Transforming growth factor, beta 3

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, TGF beta 1, Investigational New Drug, IO, TGF beta 2, Forward-looking statement, IND, Vaccine, Tumor microenvironment, Annual general meeting, Nasdaq, Peptide, EST, Immunotherapy, IDO, Center, ARG1, Society for Immunotherapy of Cancer, Securities Act of 1933, Cancer, Herlev Hospital, PD-L1, Securities Exchange Act of 1934, SITC, Time, Vaccination, Science, Transforming growth factor, beta 3, Cell, Patient, TME, Maritime Transportation Security Act of 2002, Society, Antigen, Communications satellite

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, today announced details of the invited oral presentation and two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.

Key Points: 
  • Information for the invited oral presentation:
    Session: Concurrent Session 119 Vaccines: In Situ Agents and Novel Systemic Approaches
    Presenter: Mads Hald Andersen, Ph.D.
  • We see the potential of these two new candidates to build on the strength of our T-win platform and a path forward for Investigational New Drug filings.
  • These preclinical data support further development of a TGF1 vaccine as a TME targeted approach for the treatment of a wide range of cancers.
  • IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through preclinical development its other pipeline candidates.

Allstate’s Leadership Depth Provides Strategic and Operational Continuity

Retrieved on: 
Thursday, August 18, 2022
Professional Services, Insurance, Finance, Workplace, Allstate, ALL, Life, Merten, NYSE, Chair, CEO, Transforming growth factor, beta 3, Wilson, Identity theft, Management

Allstates commitment to purpose-driven leadership supports the continued focus on improving auto insurance margins while executing its Transformative Growth strategy.

Key Points: 
  • Allstates commitment to purpose-driven leadership supports the continued focus on improving auto insurance margins while executing its Transformative Growth strategy.
  • Jess Merten will assume the Chief Financial Officer role, leveraging his broad financial and operating experience at Allstate over the last decade.
  • Allstates leadership team is aligned on building a purpose-driven company that serves customers, employees, shareholders and communities, which makes leadership transitions seamless, said Tom Wilson, Chair, President and CEO of The Allstate Corporation.
  • Marios leadership capabilities and breadth of experience during his 33 years at Allstate will ensure that this momentum is maintained.